Fig. 4. The two AMPs stimulate neutrophil migration in vivo via FPR1. (A) Vehicle, (B) scolopendrasin III (15 mg/kg), or (C) scolopendrasin V (15 mg/kg) were administrated into the peritoneal cavity of WT or FPR1-deficient mice for 2 h. Peritoneal fluid was harvested and recruited neutrophils were analyzed using FACS. Data in the panels are representative of at least three independent experiments. (D) Relative percentages of CD11b⁺ Ly6G⁺ cells from peritoneal fluid were quantified. Data are presented as means ± S.E. (n = 3-6). ***P < 0.001 compared to vehicle- treated; ^##P < 0.01 compared to WT control.